Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Company Deals

Pakistan-China Pharma Pact: $440M in Agreements Positions Pakistan as Regional Medicines Hub

Fineline Cube Jul 24, 2026
Company Deals

Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma

Fineline Cube Jul 23, 2026
Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed/Refractory DLBCL

Fineline Cube Jul 24, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA First-Line Approval for Camrelizumab-Famitinib Combo in PD-L1-Positive Cervical Cancer

Fineline Cube Jul 24, 2026
Company Drug

Sino Biopharmaceutical Ltd Receives NMPA Approval for KRAS G12C Inhibitor Garsorasib

Fineline Cube Nov 11, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company in China, has announced that it...

Company Deals Drug

Daiichi Sankyo and Alteogen Sign $300 Million Deal to Develop Subcutaneous Enhertu

Fineline Cube Nov 9, 2024

Daiichi Sankyo (TYO: 4568), a leading Japanese pharmaceutical company, has entered into a potentially $300...

Company Drug

Dizal Pharmaceutical Submits NDA to FDA for Sunvozertinib as NSCLC Therapy

Fineline Cube Nov 9, 2024

Dizal Pharmaceutical Co., Ltd (SHA: 688192), a Chinese pharmaceutical company, has announced the submission of...

Company Deals

MGI Tech Co., Ltd Partners with Human Cell Atlas Consortium to Advance Cell Mapping

Fineline Cube Nov 8, 2024

China-based gene sequencing specialist, MGI Tech Co., Ltd, (SHA: 688114) has announced a commercial collaboration...

Company

AstraZeneca Confirms Executive Vice President Leon Wang’s Detention in China

Fineline Cube Nov 8, 2024

AstraZeneca Inc., (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has provided an update to...

Company Deals

Jiangsu Kanion Pharmaceutical to Acquire Xintrum Pharmaceuticals for RMB 270 Million

Fineline Cube Nov 8, 2024

Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a China-based pharmaceutical company, has announced its intention...

Company Drug

Ascletis Pharma’s ASC47 Showcases Promising Weight Loss Results in Phase I Clinical Trial

Fineline Cube Nov 8, 2024

Ascletis Pharma Inc. (HKG: 1672), a China-based pharmaceutical company, has announced positive results from a...

Company Deals

Nuwacell Biotechnologies Secures RMB150 Million in Series B Financing for iPSC Therapies

Fineline Cube Nov 8, 2024

Nuwacell Biotechnologies Co., Ltd., a specialist in induced pluripotent stem cell (iPSC) technology based in...

Company Deals

Shanghai Henlius Biotech Partners with SVAX to Boost MENAT Region’s Access to Biological Drugs

Fineline Cube Nov 8, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), a leading Chinese biotech company, has entered into a...

Company Medical Device

Johnson & Johnson MedTech’s Varipulse Platform Receives FDA Approval for Atrial Fibrillation Treatment

Fineline Cube Nov 8, 2024

Johnson & Johnson MedTech (J&J, NYSE: JNJ) has announced that it has received marketing approval...

Company Drug

Sichuan Biokin Pharmaceutical Gets FDA Approval for Phase I Study of BL-M17D1 in Solid Tumors

Fineline Cube Nov 8, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...

Company Medical Device

Bayer AG Receives FDA 510(k) Clearance for MEDRAD Centargo CT Injection System

Fineline Cube Nov 8, 2024

Germany-based Bayer AG (ETR: BAYN) has announced that it has received 510(k) clearance from the...

Company Drug

Sichuan Huiyu Pharmaceutical’s HYP-6589 Receives NMPA Approval for Solid Tumor Clinical Trial

Fineline Cube Nov 8, 2024

Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...

Company Drug

Ascentage Pharma’s Lisaftoclax and AceLink Therapeutics’ AL01211 Receive FDA Designations

Fineline Cube Nov 8, 2024

The Center for Drug Evaluation (CDE) website has indicated that China-based Ascentage Pharma’s (HKG: 6855)...

Company Drug

AskBio’s AB-1003 Receives Rare Pediatric Disease and Orphan Drug Designations from FDA

Fineline Cube Nov 8, 2024

Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned subsidiary of Bayer AG (ETR: BAYN), has announced...

Company Deals

Teva Pharmaceutical Expands Partnerships in China’s One Health Sector with New Agreements

Fineline Cube Nov 8, 2024

Israel based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has announced new partnerships with Chinese firms...

Company Deals

Bayer’s Leap Forward: Implementing Salesforce on Alibaba Cloud for Customer Engagement

Fineline Cube Nov 8, 2024

Bayer (ETR: BAYN) has announced that its China Prescription Medicines business has fully adopted the...

Company Drug Policy / Regulatory

CDE Releases Technical Guidelines for Pilot Registration and Phased Manufacturing of ADCs

Fineline Cube Nov 8, 2024

The Center for Drug Evaluation (CDE) has issued the “Technical Requirements for Pilot Registration and...

Company Deals

Shanghai Pharmaceuticals’ MediTrust Health Partners with Eisai for Comprehensive Patient Services

Fineline Cube Nov 8, 2024

Shanghai Pharmaceuticals Holding Co., Ltd’s (HKG: 2607, SHA: 601607) subsidiary, MediTrust Health, which specializes in...

Company Deals

Boehringer Ingelheim Partners with Wuhan Union Hospital to Enhance Clinical Research and Development

Fineline Cube Nov 8, 2024

Boehringer Ingelheim, a leading German pharmaceutical company, has entered into a strategic partnership with Wuhan...

Posts pagination

1 … 303 304 305 … 699

Recent updates

  • Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed/Refractory DLBCL
  • Hengrui Pharmaceuticals Secures NMPA First-Line Approval for Camrelizumab-Famitinib Combo in PD-L1-Positive Cervical Cancer
  • Roche Reports 6% H1 Sales Growth to CHF 30.4B, Reaffirms Full-Year Guidance Amid Strong Pharmaceutical Performance
  • Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform
  • Pakistan-China Pharma Pact: $440M in Agreements Positions Pakistan as Regional Medicines Hub
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed/Refractory DLBCL

Company Drug

Hengrui Pharmaceuticals Secures NMPA First-Line Approval for Camrelizumab-Famitinib Combo in PD-L1-Positive Cervical Cancer

Company

Roche Reports 6% H1 Sales Growth to CHF 30.4B, Reaffirms Full-Year Guidance Amid Strong Pharmaceutical Performance

Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.